Skip to main content
OpenTrials
Completed

NCT Number: NCT04193566

Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes. The exact mechanisms of the beneficial effects of SGLT2 inhibition (SGLT2i) are still unknown. Kidney hypoxia has been demonstrated in diabetic kidney disease and SGLT2i is thought to relieve hypoxia in the kidneys. Mitochondrial dysfunction and autonomic dysfunction might also contribute to kidney hypoxia.

Objective: The primary aim of the study is to assess the acute effects of SGLT2 inhibition on parameters reflecting oxygenation and oxygen consumption of the human kidney in persons with type 1 diabetes. Exploratory aims are to investigate acute changes in oxygen availability and oxygen access to the kidneys after SGLT2i. This include measures of peripheral blood oxygenation, mitochondrial function and autonomic function.

Methods: Acute intervention study with oral dapagliflozin given in two doses each of 50 mg or matching placebo as intervention. Kidney oxygenation and perfusion parameters will be assessed by blood-oxygen-dependant level magnetic resonance imaging. Mitochondrial function will be assessed by extracellular flux analysis on lymphocytes. Autonomic function will be assessed by measuring baroreflex sensitivity.

Design: Randomized, double blinded, placebo-controlled, cross-over intervention study.

Study population: Fifteen healthy controls are recruited by advertisement and 15 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen.

Endpoints: Primary end-point: Renal cortical and medullary oxygenation (T2*). Exploratory end-points: Renal cortical and medullary perfusion, renal artery flow, renal oxygen consumption, peripheral capillary oxygen saturation (SpO2), arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2), lymphocyte mitochondrial function, baroreflex sensitivity.

Timeframe: Inclusion of patients from January 2020. Last patient last visit January 2021. Data analysis completed spring 2021, presentation autumn 2021 and publications Winter 2021.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

healthy controls:

  • Written informed consent must be provided before participation
  • Male or female patients > 18 years of age
  • Capable of lying in a MR-scanner for two hours

Inclusion criteria

persons with type 1 diabetes:

  • Written informed consent must be provided before participation
  • Male or female patients >18 years of age with a diagnosis of type 1 diabetes (WHO criteria)
  • Urinary albumin creatinine ratio (UACR) ≥30 mg/g in 2 out of 3 consecutive samples (albuminuria) prior to randomization assessed from electronic laboratory database.
  • Capable of lying in a MR-scanner for two hours

Exclusion criteria

for all:

  • Non-diabetic kidney disease as indicated by medical history and/or laboratory findings
  • Renal failure (eGFR<15 ml/min/1.73m2), dialysis or kidney transplantation
  • Treatment with beta-blocking medication
  • Uncontrolled arrhythmia, 2. or 3. degree AV-block or sick sinus syndrome - assessed from a standard 12-lead electrocardiogram
  • Pregnancy or breastfeeding (urine HCG is performed on all fertile women)
  • Systolic blood pressure < 90 or > 200 mmHg
  • Patients who, in the judgement of the investigator, is incapable of participating
  • Exclusion criteria for MRI
  • Claustrophobia
  • Known heart disease
  • Known lung disease
  • Have had surgery the past six weeks
  • Have foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws)
  • Exclusion criteria for arterial blood gas sampling (only patients with type 1 diabetes)
  • Absent pulse
  • Raynauds syndrome
  • Buergers Disease (thromboangiitis obliterans)
  • Inadequate or interrupted circulation
  • Anticoagulation treatment
  • Coagulopathies (hypo or hyper coagulable states)
  • Arterial atherosclerosis
  • Insufficient collateral perfusion
  • Partial or full thickness burns over the cannulation site
  • Synthetic arterial or vascular grafts or infection at the proposed site of cannulation Patients with type 1 diabetes will have the possibility to participate in the study without getting arterial blood gas sampling.

Treatment and study plan

Forxiga

Drug

Forxiga®, dapagliflozin 10 mg film-coated tablet.

For further information please refer to:

https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.

Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.

Other names: dapagliflozin

Primary outcomes

  1. Change in Renal oxygenation

    Time frame: From baseline to +3 hours from intervention

    Blood Oxygen Level Dependent (BOLD) Magnetic Resonance Imaging (MRI) assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms).

  2. Change in Renal oxygenation

    Time frame: From baseline to +6 hours from intervention

    BOLD MRI assessing the transverse relaxation time of atomic nuclei in the tissue (T2*) in miliseconds (ms).

Secondary outcomes

  1. Change in renal cortical and medullary perfusion

    Time frame: From baseline to +3 hours from intervention

    Renal tissue perfusion can be measured noninvasively with MRI using arterial spin labelling (ASL). It is measured in mL/g/min.

  2. Change in renal cortical and medullary perfusion

    Time frame: From baseline to +6 hours from intervention

    Renal tissue perfusion can be measured with MRI using arterial spin labelling (ASL). It is measured in mL/g/min.

  3. Change in renal artery flow

    Time frame: From baseline to +3 hours from intervention

    Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min.

  4. Change in renal artery flow

    Time frame: From baseline to +6 hours from intervention

    Renal artery flow can be measured by using phase contrast (PC) MRI. It is measured in mL/min.

  5. Change in renal oxygen consumption

    Time frame: From baseline to +3 hours from intervention

    Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. It is measured in pmol/min/microgram protein.

  6. Change in renal oxygen consumption

    Time frame: From baseline to +6 hours from intervention

    Renal oxygen consumption can be measured using Q-flow combined with BOLD MRI. pmol/min/microgram protein

  7. Change in peripheral capillary oxygen saturation (SpO2)

    Time frame: From baseline to +3 hours from intervention

    Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %.

  8. Change in peripheral capillary oxygen saturation (SpO2)

    Time frame: From baseline to +6 hours from intervention

    Pulse oximetry on index finger of the right hand. Estimates blood oxygen saturation from capillary blood. Measured in %.

  9. Change in blood oxygen partial pressure (PaO2)

    Time frame: From baseline to +3 hours from intervention

    Blood gas analysis on arterial blood. Measured in kPa.

  10. Change in blood oxygen partial pressure (PaO2)

    Time frame: From baseline to +6 hours from intervention

    Blood gas analysis on arterial blood. Measured in kPa.

  11. Change in arterial blood oxygen saturation

    Time frame: From baseline to +3 hours from intervention

    Blood gas analysis on arterial blood. Measured in %.

  12. Change in arterial blood oxygen saturation

    Time frame: From baseline to +6 hours from intervention

    Blood gas analysis on arterial blood. Measured in %.

  13. Change in Peripheral Blood Monocyte mitochondrial function

    Time frame: From baseline to +12 hours from intervention

    Seahorse X96 analyzer. Analyzes the oxygen consumption rate (OCR), measured in pMoles/min.

  14. Change in levels of circulating inflammatory markers

    Time frame: From baseline to +12 hours from intervention

    Commercially available panel from the company Olink. Includes 92 biomarkers. Information on the panel can be found here: https://www.olink.com/products/inflammation/#.

  15. Change in baroreflex sensitivity

    Time frame: From baseline to +12 hours from intervention

    Calculated from continous blood pressure and the distance between the R-waves in a continuous ecg. Baroreflex sensitivity describes how much heart-rate changes when blood pressure changes. Assessment of baroreflex sensitivity is done in a measurement of 5 minutes. The unit is ms/mmHg.

Sponsors and collaborators

Lead sponsor

Steno Diabetes Center Copenhagen

Other

Collaborators

  • Glostrup University Hospital, Copenhagen
  • Novo Nordisk A/S

Registry information

Official study title

Acute Effects of Sodium-glucose Cotransporter-2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

Acronym: Astronaut

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Dec 10, 2019
Registry last updated
Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.